LT3833665T - Diazabiciklooktanonai kaip serino beta-laktamazės inhibitoriai - Google Patents

Diazabiciklooktanonai kaip serino beta-laktamazės inhibitoriai

Info

Publication number
LT3833665T
LT3833665T LTEPPCT/EP2019/071370T LTEP2019071370T LT3833665T LT 3833665 T LT3833665 T LT 3833665T LT EP2019071370 T LTEP2019071370 T LT EP2019071370T LT 3833665 T LT3833665 T LT 3833665T
Authority
LT
Lithuania
Prior art keywords
diazabicyclooktanones
lactamase inhibitors
serine beta
serine
beta
Prior art date
Application number
LTEPPCT/EP2019/071370T
Other languages
English (en)
Lithuanian (lt)
Inventor
Simon Leiris
David Thomas Davies
Original Assignee
Antabio Sas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP18290093.6A external-priority patent/EP3608318A1/en
Priority claimed from EP18213635.8A external-priority patent/EP3670512A1/en
Application filed by Antabio Sas filed Critical Antabio Sas
Publication of LT3833665T publication Critical patent/LT3833665T/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
LTEPPCT/EP2019/071370T 2018-08-09 2019-08-08 Diazabiciklooktanonai kaip serino beta-laktamazės inhibitoriai LT3833665T (lt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18290093.6A EP3608318A1 (en) 2018-08-09 2018-08-09 Diaazabicyclooctanone derivatives as antibacterials
EP18213635.8A EP3670512A1 (en) 2018-12-18 2018-12-18 Diazabicyclooctanones as inhibitors of serine beta-lactamases
PCT/EP2019/071370 WO2020030761A1 (en) 2018-08-09 2019-08-08 Diazabicyclooctanones as inhibitors of serine beta-lactamases

Publications (1)

Publication Number Publication Date
LT3833665T true LT3833665T (lt) 2023-11-10

Family

ID=67667824

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEPPCT/EP2019/071370T LT3833665T (lt) 2018-08-09 2019-08-08 Diazabiciklooktanonai kaip serino beta-laktamazės inhibitoriai

Country Status (24)

Country Link
US (1) US12378244B2 (enExample)
EP (2) EP4272831A3 (enExample)
JP (1) JP7429988B2 (enExample)
KR (1) KR102790878B1 (enExample)
CN (2) CN117384155A (enExample)
AU (1) AU2019318115B2 (enExample)
BR (1) BR112021002311A2 (enExample)
CA (1) CA3110111A1 (enExample)
DK (1) DK3833665T3 (enExample)
ES (1) ES2960952T3 (enExample)
FI (1) FI3833665T3 (enExample)
HR (1) HRP20231228T1 (enExample)
HU (1) HUE063324T2 (enExample)
IL (1) IL280770B2 (enExample)
LT (1) LT3833665T (enExample)
MX (1) MX2021001564A (enExample)
PL (1) PL3833665T3 (enExample)
RS (1) RS64679B1 (enExample)
SG (1) SG11202101255UA (enExample)
SI (1) SI3833665T1 (enExample)
SM (1) SMT202300354T1 (enExample)
TW (1) TWI764030B (enExample)
WO (1) WO2020030761A1 (enExample)
ZA (1) ZA202100906B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111943950B (zh) * 2020-09-10 2022-03-29 山东安信制药有限公司 一种瑞来巴坦的制备方法
US12410166B2 (en) 2021-05-07 2025-09-09 Ningxia Academy Of Agriculture And Forestry Sciences Sulfonylamidine substituted compounds and their use as beta-lactamase inhibitors
CN115448920B (zh) * 2022-10-14 2025-01-03 广州楷石医药有限公司 一种β-内酰胺酶抑制剂及其应用
GB202306833D0 (en) 2023-05-09 2023-06-21 Adjutec Pharma As Therapy
GB202306826D0 (en) 2023-05-09 2023-06-21 Adjutec Pharma As Therapy
CN117700415B (zh) * 2024-02-06 2024-04-30 成都四面体药物研究有限公司 含脲双环化合物、其用途、其制备的药物、其联合用药物及其复方制剂
WO2025215253A1 (en) 2024-04-12 2025-10-16 Antabio Sas Dosing regimen comprising (2r,5r)-2-fluoro-7-oxo-1,6-diazabicyclo[3.2.1]octan-6-yl hydrogen sulphate and a beta-lactam antibiotic
WO2026104587A1 (en) 2024-11-13 2026-05-21 Adjutec Pharma As Cyclic boronic acid esters useful as adjuvants in the treatment of bacterial infections

Family Cites Families (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU679800B2 (en) 1993-11-06 1997-07-10 Taiho Pharmaceutical Co., Ltd. Crystalline penicillin derivative, and its production and use
CN1209099C (zh) 1999-04-01 2005-07-06 Dsm公司 结晶化附聚物
WO2001012171A2 (en) 1999-08-16 2001-02-22 Revaax Pharmaceuticals, Llc Pharmaceutical compositions comprising clavulanic acid or derivative thereof for the treatment of behavioral diseases
US20030148324A1 (en) 2001-02-02 2003-08-07 Edouard Bingen Polynucleotides which are of nature B2/D+ A- and which are isolated from E. coli, and biological uses of these polynucleotides and of their polypeptides
FR2812635B1 (fr) 2000-08-01 2002-10-11 Aventis Pharma Sa Nouveaux composes heterocycliques, preparation et utilisation comme medicaments notamment comme anti- bacteriens
SE0102058D0 (sv) 2001-06-08 2001-06-08 Astrazeneca Ab New Salts II
FR2835186B1 (fr) 2002-01-28 2006-10-20 Aventis Pharma Sa Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases
DE10218328A1 (de) 2002-03-05 2003-09-25 Humboldt Uni Zu Berlin Medizin Mittel zur präventiven Therapie nach akutem Schlaganfall
EP1342784A1 (en) 2002-03-06 2003-09-10 Mutabilis S.A. ExPEC-specific proteins, genes encoding them and uses thereof
AU2003254012B2 (en) 2002-03-13 2008-03-13 Creighton University Device and method for detecting antibiotic inactivating enzymes
FR2842210B1 (fr) 2002-07-09 2012-12-14 Mutabilis Determinants de pathogenicite utilisables comme cibles pour l'elaboration de moyens de prevention et de controle d'infections bacteriennes et/ou de la dissemination systemique
US6928313B2 (en) 2003-01-27 2005-08-09 Cardiac Pacemakers, Inc. System and method for accessing the coronary sinus to facilitate insertion of pacing leads
US20050250799A1 (en) 2004-02-05 2005-11-10 Seishiro Fujii Protease inhibitors for treatment of wrinkles
EP1580195A1 (en) 2004-03-26 2005-09-28 Mutabilis SA Compositions of polypeptides specific to pathogenic ExPEC E. coli strains and their use as vaccines and in immunotherapy
RS51506B (sr) 2004-12-02 2011-06-30 Venus Remedies Limited H. O&R&D. Smeše za suzbijanje beta-laktamazom posredovane rezistencije na antibiotike upotrebom inhibitora beta-laktamaze, korisne za injekcije
EP1669365A1 (en) 2004-12-03 2006-06-14 Mutabilis SA Method for preparing enzymatic substrate analogs as inhibitors of bacterial heptosyl-transferases
MX2007007235A (es) 2004-12-17 2007-10-19 Venus Remedies Ltd Combinacion de antibioticos para proporcionar una solucion total al tratamiento de infecciones.
AR059359A1 (es) 2006-02-09 2008-03-26 Schering Corp Formulaciones farmaceuticas que contienen pleconaril
CA2641616A1 (en) 2006-02-09 2007-08-23 Schering Corporation Pharmaceutical formulations
EP1845087A1 (en) 2006-04-14 2007-10-17 Mutabilis SA Hydroxyphenyl derivatives and biological applications thereof
CA2654968A1 (en) 2006-06-19 2008-02-21 Mutabilis Identification of genes implicated in the virulence of streptococcus agalactiae
AU2007301607A1 (en) 2006-09-25 2008-04-03 Mutabilis Sa Substituted heterocyclylcarbonylamino-acetic-acid-derivatives as inhibitors of bacterial heptose synthesis, methods for their preparation and biological applications of said inhibitors
EP1972629A1 (en) 2007-03-23 2008-09-24 Mutabilis SA New imidazolo-heteroaryl derivatives with antibacterial properties
WO2009008006A2 (en) 2007-07-06 2009-01-15 Lupin Limited Pharmaceutical compositions for gastrointestinal drug delivery
JP5038509B2 (ja) * 2008-01-18 2012-10-03 メルク・シャープ・エンド・ドーム・コーポレイション β−ラクタマーゼ阻害剤
EP2141164A1 (en) 2008-07-01 2010-01-06 Mutabilis New 1,2,4-triazine derivatives and biological applications thereof
TW201020258A (en) 2008-10-14 2010-06-01 Astrazeneca Ab Chemical compounds 542
EP2467144A1 (en) 2009-07-24 2012-06-27 ViroLogik GmbH Combination of proteasome inhibitors and anti-hepatitis medication for treating hepatitis
AU2010281739B2 (en) 2009-10-30 2011-06-09 Biogenic Innovations, Llc Use of methylsulfonylmethane (MSM) to modulate microbial activity
US8758824B2 (en) 2010-08-30 2014-06-24 Pulmatrix, Inc. Respirably dry powder comprising calcium lactate, sodium chloride and leucine
US20140024576A1 (en) 2010-12-01 2014-01-23 Laboratoire Biodim Heptose derivatives for use in the treatment of bacterial infections
SI2657234T1 (sl) 2010-12-22 2017-06-30 Meiji Seika Pharma Co., Ltd. Derivat optično-aktivnega diazabiciklooktana in metoda za njegovo izdelavo
US8829191B2 (en) 2011-06-17 2014-09-09 Melanie Simone Ronsheim Processes for preparing heterocyclic compounds including trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide and salts thereof
CA2842777C (en) 2011-07-26 2015-12-29 Wockhardt Limited Pharmaceutical compositions comprising sulbactam and beta-lactamase inhibitor
CN103649088B (zh) * 2011-08-30 2016-05-11 沃克哈特有限公司 1, 6- 二氮杂双环[3, 2, 1]辛- 7- 酮衍生物及其在治疗细菌感染中的用途
BR112014003476A2 (pt) 2011-09-13 2017-03-01 Wockhardt Ltd compostos contendo nitrogênio e seu uso
WO2013062995A1 (en) 2011-10-25 2013-05-02 Biomimetic Therapeutics, Inc. Compositions and methods for treating deep partial and full thickness wounds and injuries
WO2013062994A1 (en) 2011-10-25 2013-05-02 Biomimetic Therapeutics, Inc. Compositions and methods for treating full thickness burn injuries
US8796257B2 (en) 2011-12-02 2014-08-05 Naeja Pharmaceutical Inc. Bicyclic compounds and their use as antibacterial agents and β-lactamase inhibitors
EP2814483A2 (en) 2012-02-15 2014-12-24 Rempex Pharmaceuticals, Inc. Methods of treating bacterial infections
TW201343645A (zh) 2012-03-30 2013-11-01 Cubist Pharm Inc １，３，４－□二唑及１，３，４－噻二唑β－內醯胺酶抑制劑
JP2015512419A (ja) 2012-03-30 2015-04-27 キュービスト ファーマシューティカルズ， インコーポレイテッド イソオキザゾールβ−ラクタマーゼ阻害剤
AR090539A1 (es) * 2012-04-02 2014-11-19 Astrazeneca Ab COMPUESTOS INHIBIDORES DE b LACTAMASA
HUE046893T2 (hu) 2012-05-30 2020-04-28 Meiji Seika Pharma Co Ltd Új ß-laktamáz inhibitor és eljárás elõállítására
ES2672100T3 (es) 2012-08-25 2018-06-12 Wockhardt Limited Derivados de 1,6-diazabiciclo[3,2,1]octano-7-ona y su uso en el tratamiento de infecciones bacterianas
US20150306076A1 (en) 2012-09-27 2015-10-29 Cubist Pharmaceuticals, Inc. Tazobactam arginine antibiotic compositions
EP2725029A1 (en) 2012-10-29 2014-04-30 Laboratoire Biodim New antibacterial compounds and biological applications thereof
UA111925C2 (uk) * 2012-12-11 2016-06-24 Федора Фармасьютікалз Інк. БІЦИКЛІЧНІ СПОЛУКИ ТА ЇХ ВИКОРИСТАННЯ ЯК АНТИБАКТЕРІАЛЬНИХ АГЕНТІВ ТА ІНГІБІТОРІВ β-ЛАКТАМАЗИ
AU2014206087A1 (en) 2013-01-14 2015-05-28 Wockhardt Limited Compositions and methods for treating bacterial infections
US8889671B2 (en) 2013-01-23 2014-11-18 Astrazeneca Ab Compounds and methods for treating bacterial infections
CN104994860A (zh) 2013-02-06 2015-10-21 阿斯利康(瑞典)有限公司 用于治疗医院性肺炎的组合疗法
WO2014141132A1 (en) 2013-03-14 2014-09-18 Naeja Pharmaceutical Inc. NEW HETEROCYCLIC COMPOUNDS AND THEIR USE AS ANTIBACTERIAL AGENTS AND β-LACTAMASE INHIBITORS
US9364490B2 (en) 2013-03-15 2016-06-14 Laboratoris Sanifit, S.L. Use of derivatives containing C—O—P bonds in patients with kidney failure
ES2495666B1 (es) 2013-03-15 2015-08-10 Laboratoris Sanifit, S.L. Uso de derivados con enlaces c-o-p en pacientes con fallo renal
GB201310542D0 (en) 2013-06-13 2013-07-31 Antabio Sas Compounds
EP2821104A1 (en) 2013-07-05 2015-01-07 Laboratoire Biodim Inhibitors of viral replication, their process of preparation and their therapeutical uses
MX2016005160A (es) 2013-10-22 2016-10-05 Wockhardt Ltd Composiciones farmaceuticas que comprenden agentes antibacterianos.
CN106211771A (zh) 2014-01-21 2016-12-07 沃克哈特有限公司 含氮化合物及其作为抗菌剂的用途
EP3102578A1 (en) 2014-02-03 2016-12-14 Wockhardt Limited A process for preparation of (2s, 5r)-1,6-diaza-bicyclo [3.2.1]octane-2-carbonitrile-7-oxo-6-(sulfooxy)-mono sodium salt
WO2015125031A1 (en) 2014-02-20 2015-08-27 Wockhardt Limited Pharmaceutical combinations comprising antibacterial agents
EP2913330A1 (en) 2014-02-27 2015-09-02 Laboratoire Biodim Condensed derivatives of imidazole useful as pharmaceuticals
WO2015136387A1 (en) 2014-03-14 2015-09-17 Wockhardt Limited Pharmaceutical compositions comprising antibacterial agents
HUE042134T2 (hu) 2014-03-24 2019-06-28 Novartis Ag Monobaktám szerves vegyületek bakteriális fertõzések kezelésére
EP3131583A1 (en) 2014-04-18 2017-02-22 The Wockhardt Limited Pharmaceutical compositions comprising antibacterial agents
WO2015159167A1 (en) 2014-04-18 2015-10-22 Wockhardt Limited Pharmaceutical compositions comprising antibacterial agents
SG11201609404SA (en) 2014-05-29 2016-12-29 Entasis Therapeutics Ltd Fused, spirocyclic heteroaromatic compounds for the treatment of bacterial infections
US20150361108A1 (en) 2014-06-11 2015-12-17 VenatoRx Pharmaceuticals, Inc. Orally bioavailable beta-lactamase inhibitors
TWI690317B (zh) 2014-11-17 2020-04-11 英商安特西醫療有限公司 用於治療抗藥性細菌感染之組合療法
GB2533136A (en) 2014-12-11 2016-06-15 Antabio Sas Compounds
WO2016116788A1 (en) 2015-01-24 2016-07-28 Wockhardt Limited Nitrogen containing bicyclic compounds and their use in treatment of bacterial infections
WO2016128867A1 (en) 2015-02-12 2016-08-18 Wockhardt Limited Azetidinone containing compounds and their use in treatment of bacterial infections
CA2980085A1 (en) 2015-03-31 2016-10-06 Mutabilis Novel heterocyclic compounds and their use in preventing or treating bacterial infections
HK1244791A1 (zh) 2015-03-31 2018-08-17 拜欧蒂姆公司 杂环化合物及它们在预防或治疗细菌感染中的应用
EP3277277B1 (en) 2015-04-03 2021-01-06 Mutabilis Heterocyclic compounds and their use in preventing or treating bacterial infections
CN107580595B (zh) 2015-05-07 2020-09-18 拜欧蒂姆公司 杂环化合物及它们在预防或治疗细菌感染中的应用
WO2017002089A1 (en) 2015-07-02 2017-01-05 Wockhardt Limited Nitrogen containing bicyclic compounds and their use in treatment of bacterial infections
WO2017002083A1 (en) 2015-07-02 2017-01-05 Wockhardt Limited Nitrogen containing bicyclic compounds and their use in treatment of bacterial infections
WO2017002087A1 (en) 2015-07-02 2017-01-05 Wockhardtlimited Nitrogen containing bicyclic compounds and their use in treatment of bacterial infections
WO2017002086A1 (en) 2015-07-02 2017-01-05 Wockhardt Limited Nitrogen containing bicyclic compounds and their use in treatment of bacterial infections
CN106467705B (zh) 2015-08-17 2019-02-22 3M创新有限公司 防滑液、防滑件及其制备方法
WO2017037607A1 (en) 2015-09-01 2017-03-09 Wockhardt Limited (aminomethylidene)amino-substituted (2s,5r)-6-(sulfonyl)-7-oxo-1,6-diazabicyclo[3.2.1 ]octane-2-carboxamide derivatives with antibacterial activity
US9751894B2 (en) 2015-12-10 2017-09-05 Naeja-Rgm Pharmaceuticals Inc. Cephem compounds, their production and use
EP3184529A1 (en) 2015-12-23 2017-06-28 Mutabilis Heterocyclic compounds and their use in preventing or treating bacterial infections
EP3426391A4 (en) 2016-03-11 2019-08-28 California Institute of Technology COMPOSITIONS AND METHODS FOR ACYLATING LACTAMEN
WO2017203266A1 (en) 2016-05-25 2017-11-30 Entasis Therapeutics Limited Combination therapy for treatment of resistant bacterial infections
CN109310682A (zh) 2016-06-17 2019-02-05 沃克哈特有限公司 抗菌组合物
SG11201901658PA (en) 2016-09-16 2019-04-29 Entasis Therapeutics Ltd Beta-lactamase inhibitor compounds
EP3300736B1 (en) 2016-09-30 2021-05-05 Mutabilis Composition comprising antibiotic compound and an heterocyclic compound and their use in preventing or treating bacterial infections
WO2018129008A1 (en) 2017-01-04 2018-07-12 Entasis Therapeutics Inc. Compounds and methods for treating bacterial infections
EP3357924A1 (en) 2017-02-06 2018-08-08 Mutabilis Novel heterocyclic compounds and their use in preventing or treating bacterial infections
WO2018141991A1 (en) 2017-02-06 2018-08-09 Mutabilis Novel heterocyclic compounds and their use in preventing or treating bacterial infections
PT3630111T (pt) 2017-05-08 2022-03-01 Entasis Therapeutics Inc Compostos e métodos de tratamento de infeções bacterianas
KR20200030584A (ko) * 2017-07-21 2020-03-20 앤타바이오 에스에이에스 화합물
CN107501265B (zh) * 2017-10-09 2019-05-28 台州职业技术学院 一种7-氧代-二氮杂二环[3,2,1]辛烷衍生化合物及其制备方法和应用
WO2019093450A1 (ja) * 2017-11-10 2019-05-16 塩野義製薬株式会社 ジアザビシクロオクタン誘導体
EP3572411A1 (en) 2018-05-21 2019-11-27 Antabio SAS Thiazole derivatives as metallo-beta-lactamase inhibitors
EP3604315A1 (en) 2018-07-30 2020-02-05 Mutabilis Heterocyclic compounds and their use in preventing or treating bacterial infections
EP3604309A1 (en) 2018-07-30 2020-02-05 Mutabilis Heterocyclic compounds and their use in preventing or treating bacterial infections
US11905286B2 (en) * 2018-08-09 2024-02-20 Antabio Sas Diazabicyclooctanones as inhibitors of serine beta-lactamases

Also Published As

Publication number Publication date
HRP20231228T1 (hr) 2024-01-19
EP3833665B1 (en) 2023-07-19
KR102790878B1 (ko) 2025-04-02
SI3833665T1 (sl) 2023-12-29
AU2019318115B2 (en) 2024-04-18
ZA202100906B (en) 2023-07-26
CN117384155A (zh) 2024-01-12
TWI764030B (zh) 2022-05-11
EP3833665A1 (en) 2021-06-16
PL3833665T3 (pl) 2023-12-27
IL280770B1 (en) 2024-01-01
KR20210055701A (ko) 2021-05-17
SG11202101255UA (en) 2021-03-30
US20240391919A1 (en) 2024-11-28
AU2019318115A1 (en) 2021-03-11
SMT202300354T1 (it) 2023-11-13
JP2021534095A (ja) 2021-12-09
DK3833665T3 (da) 2023-10-09
EP4272831A2 (en) 2023-11-08
HUE063324T2 (hu) 2024-01-28
JP7429988B2 (ja) 2024-02-09
CA3110111A1 (en) 2020-02-13
RS64679B1 (sr) 2023-11-30
MX2021001564A (es) 2021-05-12
FI3833665T3 (fi) 2023-10-09
IL280770A (en) 2021-04-29
TW202019929A (zh) 2020-06-01
IL280770B2 (en) 2024-05-01
US12378244B2 (en) 2025-08-05
ES2960952T3 (es) 2024-03-07
EP4272831A3 (en) 2024-02-21
BR112021002311A2 (pt) 2021-05-04
WO2020030761A1 (en) 2020-02-13
CN111954671B (zh) 2023-09-01
CN111954671A (zh) 2020-11-17

Similar Documents

Publication Publication Date Title
IL283639A (en) Kif18a inhibitors
IL282535A (en) Substituted 6-azabenzimidazole compounds as hpk1 inhibitors
CY1125826T1 (el) Ενωσεις αναστολεις της βητα-λακταμασης
EP4007756C0 (en) KIF18A INHIBITORS
EP3843714C0 (en) CD73 INHIBITORS
EP3898592C0 (en) HETEROARYL AMIDES USEFUL AS KIF18A INHIBITORS
EP3898616C0 (en) HETEROARYL AMIDES USEFUL AS KIF18A INHIBITORS
MA54550A (fr) Inhibiteurs de kif18a
EP3761992A4 (en) ARGINASE INHIBITORS
MA52812A (fr) Inhibiteurs de sarm1
DK3497103T3 (da) Pyridopyrimdinon-cdk2/4/6-inhibitorer
EP3801500A4 (en) Inhibitors of sarm1
PL3833665T3 (pl) Diazabicykloktanony jako inhibitory beta-laktamaz serynowych
DK4051688T3 (da) Cd73-hæmmere
EP3801499A4 (en) INHIBITORS OF SARM1
DK3261639T3 (da) Substituerede pyrazolforbindelser som serinproteaseinhibitorer
EP3980011C0 (en) SARM1 HIBITORS
EP3609882A4 (en) Heterocyclic inhibitors of pcsk9
EP3947366C0 (en) HPK1 INHIBITORS
EP3947373C0 (en) BICYCLIC HPK1 INHIBITORS
EP3817736A4 (en) PIKFYVE INHIBITORS
EP3790871C0 (en) FURIN INHIBITORS
IL281514A (en) O-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors
EP4003986A4 (en) Inhibitor compounds
MA51611A (fr) Inhibiteurs de pi4kiiibêta